Last reviewed · How we verify
Use of bromfenac 0.09% to reduce intravitreal injection pain
Use of bromfenac 0.09% to reduce intravitreal injection pain is a Small molecule drug developed by Wills Eye. It is currently FDA-approved.
Bromfenac 0.09%, marketed by Wills Eye, is a non-steroidal anti-inflammatory drug (NSAID) used to reduce pain associated with intravitreal injections. The key composition patent for bromfenac 0.09% is set to expire in 2028, providing a clear period of market exclusivity. The primary risk is the potential for increased competition once the patent expires.
At a glance
| Generic name | Use of bromfenac 0.09% to reduce intravitreal injection pain |
|---|---|
| Sponsor | Wills Eye |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Use of bromfenac 0.09% to reduce intravitreal injection pain CI brief — competitive landscape report
- Use of bromfenac 0.09% to reduce intravitreal injection pain updates RSS · CI watch RSS
- Wills Eye portfolio CI